RESEARCH: HALOGENASES
FOLDING PROJECT #19210 PROFILE

Many new medicines use halogens (like chlorine and iodine). Adding these is tricky because it can be hard to control where they go. Scientists are studying special enzymes called halogenases that do this perfectly. This project uses computer models to predict how well different enzymes add halogens to different molecules.

Note: This TLDR is a simplication and may not be 100% accurate.

Approximately 40 percent of drugs approved or currently in clinical testing contain halogens (F, Cl, Br, or I) as pharmaceutically active ligand substituents.

This makes the halogenation of chemical scaffolds an issue of particular interest to medicinal chemists when attempting to synthesize potential drug candidates.

Many of the current methods for halogenation are difficult to control the regioselectivity or produce toxic byproducts during the reaction.

Due to these issues; halogenases, a class of enzymes that catalyze highly regioselective halogenation of various molecules in nature, have been studied as a means to improve existing halogenation methods with less toxic byproducts and higher regioselectivity of reaction.

By utilizing Relative Binding Free Energy calculations (RBFE) across a number of common organic molecule scaffolds, our goal is to better predict the probability and site of halogenation for various common chemical scaffolds across a number of halogenases.

---

halogens

Elements fluorine (F), chlorine (Cl), bromine (Br), and iodine (I).

Halogens are highly reactive non-metallic elements that can be used to modify chemical compounds in pharmaceuticals. They often play a crucial role in drug activity by influencing how a drug binds to its target.

---

pharmaceutically active ligand

A molecule that binds to a biological target (like a receptor) and produces a pharmacological effect.

This term refers to the part of a drug molecule that interacts with a specific target in the body. This interaction is what ultimately causes the drug's therapeutic effect.

---

medicinal chemists

Scientists who design and synthesize new drug molecules.

Medicinal chemists are responsible for developing new drugs by creating and testing different chemical compounds. They combine knowledge of chemistry, biology, and pharmacology to create effective and safe medications.

---

regioselectivity

The preferential formation of one product isomer over others in a chemical reaction.

Regioselectivity refers to the tendency of a chemical reaction to produce a specific type of molecule when there are multiple possible outcomes. This is important in drug development because it ensures that the desired drug molecule is formed preferentially.

---

halogenases

Enzymes that catalyze the regioselective halogenation of molecules.

Halogenases are a class of enzymes found in nature that can add halogens (like chlorine or bromine) to organic molecules. These enzymes offer a more environmentally friendly and precise way to modify chemicals compared to traditional methods.

---

Relative Binding Free Energy calculations (RBFE)

A computational method used to predict the binding affinity of a molecule to a target.

RBFE calculations are a powerful tool in drug discovery. They allow scientists to virtually test how well different molecules bind to potential drug targets, helping them identify promising candidates for further development.